Structural and sequential context of p53: A review of experimental and theoretical evidence

Progress in Biophysics and Molecular Biology

Volumn 117, Issue 2-3, 2015, Pages 250-263

  Saha, Taniya ^a   Kar, Rajiv K ^a   Sa, Gaurisankar ^a  

^a BOSE INSTITUTE   (India)

Author keywords

Molecular dynamics simulation; Mutation; p53; Small molecule inhibitor; Thermodynamic

Indexed keywords

DNA; PROTEIN BINDING; PROTEIN MDM2; PROTEIN P53;

AMINO ACID SEQUENCE; ANIMAL; BINDING SITE; CHEMICAL MODEL; CHEMISTRY; COMPUTER SIMULATION; GENETICS; HUMAN; MOLECULAR DYNAMICS; MOLECULAR GENETICS; MUTATION; PROTEIN CONFORMATION; STRUCTURE ACTIVITY RELATION; ULTRASTRUCTURE;

AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; COMPUTER SIMULATION; DNA; HUMANS; MODELS, CHEMICAL; MOLECULAR DYNAMICS SIMULATION; MOLECULAR SEQUENCE DATA; MUTATION; PROTEIN BINDING; PROTEIN CONFORMATION; PROTO-ONCOGENE PROTEINS C-MDM2; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84938963394     PISSN: 00796107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbiomolbio.2014.12.002     Document Type: Review

References (174)

1. Adorno M., Cordenonsi M., Montagner M., Dupont S., Wong C., Hann B., Solari A., Bobisse S., Rondina M.B., Guzzardo V., Parenti A.R., Rosato A., Bicciato S., Balmain A., Piccolo S. A mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 2009, 137:87-98.
2. Agapova L.S., Ilyinskaya G.V., Turovets N.A., Ivanov A.V., Chumakov P.M., Kopnin B.P. Chromosome changes caused by alterations of p53 expression. Mutat. Res. 1996, 354:129-138.
3. Ang H.C., Joerger A.C., Mayer S., Fersht A.R. Effects of common cancer mutations on stability and DNA binding of full-length p53 compared with isolated core domains. J. Biol. Chem. 2006, 281:21934-21941.
4. Ashcroft M., Kubbutat M.H., Vousden K.H. Regulation of p53 function and stability by phosphorylation. Mol. Cell. Biol. 1999, 19:1751-1758.
5. Barakat K., Issack B.B., Stepanova M., Tuszynski J. Effects of temperature on the p53-DNA binding interactions and their dynamical behavior: comparing the wild type to the R248Q mutant. PLoS One 2011, 6:e27651.
6. Barlev N.A., Liu L., Chehab N.H., Mansfield K., Harris K.G., Halazonetis T.D., Berger S.L. Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol. Cell. 2001, 8:1243-1254.
7. Bech-Otschir D., Kraft R., Huang X., Henklein P., Kapelari B., Pollmann C., Dubiel W. COP9 signalosome-specific phosphorylation targets p53 to degradation by the ubiquitin system. EMBO J. 2001, 20:1630-1639.
8. Bell S., Klein C., Müller L., Hansen S., Buchner J. p53 contains large unstructured regions in its native state. J. Mol. Biol. 2002, 322:917-927.
9. Belyi V.A., Ak P., Markert E., Wang H., Hu W., Puzio-Kuter A., Levine A.J. The origins and evolution of the p53 family of genes. Cold Spring Harb. Perspect. Biol. 2010, 2:a001198.
10. Belyi V.A., Levine A.J. One billion years of p53/p63/p73 evolution. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:17609-17610.
11. Brown C.J., Cheok C.F., Verma C.S., Lane D.P. Reactivation of p53: from peptides to small molecules. Trends Pharmacol. Sci. 2011, 32:53-62.
12. Brown C.J., Lain S., Verma C.S., Fersht A.R., Lane D.P. Awakening guardian angels: drugging the p53 pathway. Nat. Rev. Cancer 2009, 9:862-873.
13. Brown C.J., Quah S.T., Jong J., Goh A.M., Chiam P.C., Khoo K.H., Choong M.L., Lee M.A., Yurlova L., Zolghadr K., Joseph T.L., Verma C.S., Lane D.P. Stapled peptides with improved potency and specificity that activate p53. ACS Chem. Biol. 2013, 8:506-512.
14. Bulavin D.V., Saito S., Hollander M.C., Sakaguchi K., Anderson C.W., Appella E., Fornace A.J. Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation. EMBO J. 1999, 18:6845-6854.
15. Bullock A.N., Henckel J., DeDecker B.S., Johnson C.M., Nikolova P.V., Proctor M.R., Lane D.P., Fersht A.R. Thermodynamic stability of wild-type and mutant p53 core domain. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:14338-14342.
16. Bullock A.N., Henckel J., Fersht A.R. Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene 2000, 19:1245-1256.
17. Buschmann T., Potapova O., Bar-Shira A., Ivanov V.N., Fuchs S.Y., Henderson S., Fried V.A., Minamoto T., Alarcon-Vargas D., Pincus M.R., Gaarde W.A., Holbrook N.J., Shiloh Y., Ronai Z. Jun NH2-terminal kinase phosphorylation of p53 on Thr-81 is important for p53 stabilization and transcriptional activities in response to stress. Mol. Cell. Biol. 2001, 21:2743-2754.
18. Bykov V.J., Issaeva N., Shilov A., Hultcrantz M., Pugacheva E., Chumakov P., Bergman J., Wiman K.G., Selivanova G. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat. Med. 2002, 8:282-288.
19. Bykov V.J., Issaeva N., Zache N., Shilov A., Hultcrantz M., Bergman J., Selivanova G., Wiman K.G. Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs. J. Biol. Chem. 2005, 280:30384-30391.
20. Bykov V.J., Wiman K.G. Mutant p53 reactivation by small molecules makes its way to the clinic. FEBS Lett. 2014, 588:2622-2627.
21. Cañadillas J.M., Tidow H., Freund S.M., Rutherford T.J., Ang H.C., Fersht A.R. Solution structure of p53 core domain: structural basis for its instability. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:2109-2114.
22. Cesková P., Chichger H., Wallace M., Vojtesek B., Hupp T.R. On the mechanism of sequence-specific DNA-dependent acetylation of p53: the acetylation motif is exposed upon DNA binding. J. Mol. Biol. 2006, 357:442-456.
23. Chehab N.H., Malikzay A., Stavridi E.S., Halazonetis T.D. Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:13777-13782.
24. Chen L., Chen J. MDM2-ARF complex regulates p53 sumoylation. Oncogene 2003, 22:5348-5357.
25. Chen Y., Chen P.L., Lee W.H. Hot-spot p53 mutants interact specifically with two cellular proteins during progression of the cell cycle. Mol. Cell. Biol. 1994, 14:6764-6772.
26. Cho K.I., Kim D., Lee D. A feature-based approach to modeling protein-protein interaction hot spots. Nucleic Acids Res. 2009, 37:2672-2687.
27. Cho Y., Gorina S., Jeffrey P.D., Pavletich N.P. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 1994, 265:346-355.
28. Chène P. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat. Rev. Cancer 2003, 3:102-109.
29. Cicero D.O., Falconi M., Candi E., Mele S., Cadot B., Di Venere A., Rufini S., Melino G., Desideri A. NMR structure of the p63 SAM domain and dynamical properties of G534V and T537P pathological mutants, identified in the AEC syndrome. Cell. Biochem. Biophys. 2006, 44:475-489.
30. Craig A.L., Burch L., Vojtesek B., Mikutowska J., Thompson A., Hupp T.R. Novel phosphorylation sites of human tumour suppressor protein p53 at Ser20 and Thr18 that disrupt the binding of mdm2 (mouse double minute 2) protein are modified in human cancers. Biochem. J. 1999, 342(Pt 1):133-141.
31. Crunkhorn S. Anticancer drugs: stapled peptide rescues p53. Nat. Rev. Drug Discov. 2011, 10:21.
32. Dawson R., Müller L., Dehner A., Klein C., Kessler H., Buchner J. The N-terminal domain of p53 is natively unfolded. J. Mol. Biol. 2003, 332:1131-1141.
33. Dell'Orco D. Fast predictions of thermodynamics and kinetics of protein-protein recognition from structures: from molecular design to systems biology. Mol. Biosyst. 2009, 5:323-334.
34. Demir Ö., Baronio R., Salehi F., Wassman C.D., Hall L., Hatfield G.W., Chamberlin R., Kaiser P., Lathrop R.H., Amaro R.E. Ensemble-based computational approach discriminates functional activity of p53 cancer and rescue mutants. PLoS Comput. Biol. 2011, 7:e1002238.
35. 2+ on DNA recognition and stability of the p53 DNA-binding domain. Biochemistry 2006, 45:7483-7492.
36. Dumaz N., Milne D.M., Meek D.W. Protein kinase CK1 is a p53-threonine 18 kinase which requires prior phosphorylation of serine 15. FEBS Lett. 1999, 463:312-316.
37. Duncan S.J., Grüschow S., Williams D.H., McNicholas C., Purewal R., Hajek M., Gerlitz M., Martin S., Wrigley S.K., Moore M. Isolation and structure elucidation of Chlorofusin, a novel p53-MDM2 antagonist from a Fusarium sp. J. Am. Chem. Soc. 2001, 123:554-560.
38. Dötsch V., Bernassola F., Coutandin D., Candi E., Melino G. p63 and p73, the ancestors of p53. Cold Spring Harb. Perspect. Biol. 2010, 2:a004887.
39. Eichenbaum K.D., Rodríguez Y., Mezei M., Osman R. The energetics of the acetylation switch in p53-mediated transcriptional activation. Proteins 2010, 78:447-456.
40. el-Deiry W.S., Kern S.E., Pietenpol J.A., Kinzler K.W., Vogelstein B. Definition of a consensus binding site for p53. Nat. Genet. 1992, 1:45-49.
41. Eldar A., Rozenberg H., Diskin-Posner Y., Rohs R., Shakked Z. Structural studies of p53 inactivation by DNA-contact mutations and its rescue by suppressor mutations via alternative protein-DNA interactions. Nucleic Acids Res. 2013, 41:8748-8759.
42. ElSawy K.M., Verma C.S., Joseph T.L., Lane D.P., Twarock R., Caves L.S. On the interaction mechanisms of a p53 peptide and nutlin with the MDM2 and MDMX proteins: a Brownian dynamics study. Cell. Cycle 2013, 12:394-404.
43. ElSawy K.M., Verma C.S., Lane D.P., Caves L.S. On the origin of the stereoselective affinity of Nutlin-3 geometrical isomers for the MDM2 protein. Cell. Cycle 2013, 12:3727-3735.
44. Espinoza-Fonseca L.M., Trujillo-Ferrara J.G. Transient stability of the helical pattern of region F19-L22 of the N-terminal domain of p53: a molecular dynamics simulation study. Biochem. Biophys. Res. Commun. 2006, 343:110-116.
45. Falconi M., Melino G., Desideri A. Molecular dynamics simulation of the C-terminal sterile alpha-motif domain of human p73alpha: evidence of a dynamical relationship between helices 3 and 5. Biochem. Biophys. Res. Commun. 2004, 316:1037-1042.
46. Fan Q.D., Wu G., Liu Z.R. Dynamics of posttranslational modifications of p53. Comput. Math. Methods Med. 2014, 2014:245610.
47. Ferrone M., Perrone F., Tamborini E., Paneni M.S., Fermeglia M., Suardi S., Pastore E., Delia D., Pierotti M.A., Pricl S., Pilotti S. Functional analysis and molecular modeling show a preserved wild-type activity of p53(C238Y). Mol. Cancer Ther. 2006, 5:1467-1473.
48. Fraser J.A., Madhumalar A., Blackburn E., Bramham J., Walkinshaw M.D., Verma C., Hupp T.R. A novel p53 phosphorylation site within the MDM2 ubiquitination signal: II. A model in which phosphorylation at SER269 induces a mutant conformation to p53. J. Biol. Chem. 2010, 285:37773-37786.
49. Fraser J.A., Vojtesek B., Hupp T.R. A novel p53 phosphorylation site within the MDM2 ubiquitination signal: I. phosphorylation at SER269 in vivo is linked to inactivation of p53 function. J. Biol. Chem. 2010, 285:37762-37772.
50. Friedler A., Veprintsev D.B., Hansson L.O., Fersht A.R. Kinetic instability of p53 core domain mutants: implications for rescue by small molecules. J. Biol. Chem. 2003, 278:24108-24112.
51. Funk W.D., Pak D.T., Karas R.H., Wright W.E., Shay J.W. A transcriptionally active DNA-binding site for human p53 protein complexes. Mol. Cell. Biol. 1992, 12:2866-2871.
52. Gaiddon C., Lokshin M., Ahn J., Zhang T., Prives C. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol. Cell. Biol. 2001, 21:1874-1887.
53. Gatti A., Li H.H., Traugh J.A., Liu X. Phosphorylation of human p53 on Thr-55. Biochemistry 2000, 39:9837-9842.
54. Greenblatt M.S., Beaudet J.G., Gump J.R., Godin K.S., Trombley L., Koh J., Bond J.P. Detailed computational study of p53 and p16: using evolutionary sequence analysis and disease-associated mutations to predict the functional consequences of allelic variants. Oncogene 2003, 22:1150-1163.
55. Guerois R., Nielsen J.E., Serrano L. Predicting changes in the stability of proteins and protein complexes: a study of more than 1000 mutations. J. Mol. Biol. 2002, 320:369-387.
56. Hainaut P., Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv. Cancer Res. 2000, 77:81-137.
57. Hamelberg D., Shen T., McCammon J.A. Phosphorylation effects on cis/trans isomerization and the backbone conformation of serine-proline motifs: accelerated molecular dynamics analysis. J. Am. Chem. Soc. 2005, 127:1969-1974.
58. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
59. Harris C.C., Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N. Engl. J. Med. 1993, 329:1318-1327.
60. Hernychova L., Man P., Verma C., Nicholson J., Sharma C.A., Ruckova E., Teo J.Y., Ball K., Vojtesek B., Hupp T.R. Identification of a second Nutlin-3 responsive interaction site in the N-terminal domain of MDM2 using hydrogen/deuterium exchange mass spectrometry. Proteomics 2013, 13:2512-2525.
61. Huang Q., Yu L., Levine A.J., Nussinov R., Ma B. Dipeptide analysis of p53 mutations and evolution of p53 family proteins. Biochim. Biophys. Acta 2014, 1844:198-206.
62. Issaeva N., Bozko P., Enge M., Protopopova M., Verhoef L.G., Masucci M., Pramanik A., Selivanova G. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat. Med. 2004, 10:1321-1328.
63. Jenkins L.M., Durell S.R., Mazur S.J., Appella E. p53 N-terminal phosphorylation: a defining layer of complex regulation. Carcinogenesis 2012, 33:1441-1449.
64. Jiang D., Brady C.A., Johnson T.M., Lee E.Y., Park E.J., Scott M.P., Attardi L.D. Full p53 transcriptional activation potential is dispensable for tumor suppression in diverse lineages. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:17123-17128.
65. Joerger A.C., Allen M.D., Fersht A.R. Crystal structure of a superstable mutant of human p53 core domain. Insights into the mechanism of rescuing oncogenic mutations. J. Biol. Chem. 2004, 279:1291-1296.
66. Joerger A.C., Ang H.C., Fersht A.R. Structural basis for understanding oncogenic p53 mutations and designing rescue drugs. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:15056-15061.
67. Joerger A.C., Ang H.C., Veprintsev D.B., Blair C.M., Fersht A.R. Structures of p53 cancer mutants and mechanism of rescue by second-site suppressor mutations. J. Biol. Chem. 2005, 280:16030-16037.
68. Joerger A.C., Fersht A.R. Structural biology of the tumor suppressor p53 and cancer-associated mutants. Adv. Cancer Res. 2007, 97:1-23.
69. Joerger A.C., Fersht A.R. Structure-function-rescue: the diverse nature of common p53 cancer mutants. Oncogene 2007, 26:2226-2242.
70. Joerger A.C., Fersht A.R. Structural biology of the tumor suppressor p53. Annu. Rev. Biochem. 2008, 77:557-582.
71. Joerger A.C., Fersht A.R. The tumor suppressor p53: from structures to drug discovery. Cold Spring Harb. Perspect. Biol. 2010, 2:a000919.
72. Joseph T.L., Madhumalar A., Brown C.J., Lane D.P., Verma C.S. Differential binding of p53 and nutlin to MDM2 and MDMX: computational studies. Cell. Cycle 2010, 9:1167-1181.
73. Kaar J.L., Basse N., Joerger A.C., Stephens E., Rutherford T.J., Fersht A.R. Stabilization of mutant p53 via alkylation of cysteines and effects on DNA binding. Protein Sci. 2010, 19:2267-2278.
74. Kalid O., Ben-Tal N. Study of MDM2 binding to p53-analogues: affinity, helicity, and applicability to drug design. J. Chem. Inf. Model. 2009, 49:865-876.
75. Kar S., Sakaguchi K., Shimohigashi Y., Samaddar S., Banerjee R., Basu G., Swaminathan V., Kundu T.K., Roy S. Effect of phosphorylation on the structure and fold of transactivation domain of p53. J. Biol. Chem. 2002, 277:15579-15585.
76. Katayama H., Sasai K., Kawai H., Yuan Z.M., Bondaruk J., Suzuki F., Fujii S., Arlinghaus R.B., Czerniak B.A., Sen S. Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat. Genet. 2004, 36:55-62.
77. Keller D.M., Zeng X., Wang Y., Zhang Q.H., Kapoor M., Shu H., Goodman R., Lozano G., Zhao Y., Lu H. A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, and SSRP1. Mol. Cell. 2001, 7:283-292.
78. Khazanov N., Levy Y. Sliding of p53 along DNA can be modulated by its oligomeric state and by cross-talks between its constituent domains. J. Mol. Biol. 2011, 408:335-355.
79. Khoo K.H., Andreeva A., Fersht A.R. Adaptive evolution of p53 thermodynamic stability. J. Mol. Biol. 2009, 393:161-175.
80. Kim Y.W., Grossmann T.N., Verdine G.L. Synthesis of all-hydrocarbon stapled α-helical peptides by ring-closing olefin metathesis. Nat. Protoc. 2011, 6:761-771.
81. Kitayner M., Rozenberg H., Kessler N., Rabinovich D., Shaulov L., Haran T.E., Shakked Z. Structural basis of DNA recognition by p53 tetramers. Mol. Cell. 2006, 22:741-753.
82. Klein-Seetharaman J., Oikawa M., Grimshaw S.B., Wirmer J., Duchardt E., Ueda T., Imoto T., Smith L.J., Dobson C.M., Schwalbe H. Long-range interactions within a nonnative protein. Science 2002, 295:1719-1722.
83. Kogan-Sakin I., Tabach Y., Buganim Y., Molchadsky A., Solomon H., Madar S., Kamer I., Stambolsky P., Shelly A., Goldfinger N., Valsesia-Wittmann S., Puisieux A., Zundelevich A., Gal-Yam E.N., Avivi C., Barshack I., Brait M., Sidransky D., Domany E., Rotter V. Mutant p53(R175H) upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells. Cell. Death Differ. 2011, 18:271-281.
84. Koulgi S., Achalere A., Sharma N., Sonavane U., Joshi R. QM-MM simulations on p53-DNA complex: a study of hot spot and rescue mutants. J. Mol. Model. 2013, 19:5545-5559.
85. Kravchenko J.E., Ilyinskaya G.V., Komarov P.G., Agapova L.S., Kochetkov D.V., Strom E., Frolova E.I., Kovriga I., Gudkov A.V., Feinstein E., Chumakov P.M. Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:6302-6307.
86. Kussie P.H., Gorina S., Marechal V., Elenbaas B., Moreau J., Levine A.J., Pavletich N.P. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 1996, 274:948-953.
87. Lain S., Hollick J.J., Campbell J., Staples O.D., Higgins M., Aoubala M., McCarthy A., Appleyard V., Murray K.E., Baker L., Thompson A., Mathers J., Holland S.J., Stark M.J., Pass G., Woods J., Lane D.P., Westwood N.J. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell. 2008, 13:454-463.
88. Lambert J.M., Gorzov P., Veprintsev D.B., Söderqvist M., Segerbäck D., Bergman J., Fersht A.R., Hainaut P., Wiman K.G., Bykov V.J. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell. 2009, 15:376-388.
89. Lane D.P., Brown C.J., Verma C., Cheok C.F. New insights into p53 based therapy. Discov. Med. 2011, 12:107-117.
90. Lee H., Mok K.H., Muhandiram R., Park K.H., Suk J.E., Kim D.H., Chang J., Sung Y.C., Choi K.Y., Han K.H. Local structural elements in the mostly unstructured transcriptional activation domain of human p53. J. Biol. Chem. 2000, 275:29426-29432.
91. Lee H.J., Srinivasan D., Coomber D., Lane D.P., Verma C.S. Modulation of the p53-MDM2 interaction by phosphorylation of Thr18: a computational study. Cell. Cycle 2007, 6:2604-2611.
92. Lev Bar-Or R., Maya R., Segel L.A., Alon U., Levine A.J., Oren M. Generation of oscillations by the p53-Mdm2 feedback loop: a theoretical and experimental study. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:11250-11255.
93. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell 1997, 88:323-331.
94. Levrero M., De Laurenzi V., Costanzo A., Gong J., Melino G., Wang J.Y. Structure, function and regulation of p63 and p73. Cell. Death Differ. 1999, 6:1146-1153.
95. Levrero M., De Laurenzi V., Costanzo A., Gong J., Wang J.Y., Melino G. The p53/p63/p73 family of transcription factors: overlapping and distinct functions. J. Cell. Sci. 2000, 113(Pt 10):1661-1670.
96. Li H.H., Li A.G., Sheppard H.M., Liu X. Phosphorylation on Thr-55 by TAF1 mediates degradation of p53: a role for TAF1 in cell G1 progression. Mol. Cell. 2004, 13:867-878.
97. Li J., Yang L., Gaur S., Zhang K., Wu X., Yuan Y.C., Li H., Hu S., Weng Y., Yen Y. Mutants TP53 p.R273H and p.R273C but not p.R273G enhance cancer cell malignancy. Hum. Mutat. 2014, 35:575-584.
98. Libermann T.A., Zerbini L.F. Targeting transcription factors for cancer gene therapy. Curr. Gene Ther. 2006, 6:17-33.
99. Lim L.Y., Vidnovic N., Ellisen L.W., Leong C.O. Mutant p53 mediates survival of breast cancer cells. Br. J. Cancer 2009, 101:1606-1612.
100. Lu Q., Tan Y.H., Luo R. Molecular dynamics simulations of p53 DNA-binding domain. J. Phys. Chem. B 2007, 111:11538-11545.
101. Lubin D.J., Butler J.S., Loh S.N. Folding of tetrameric p53: oligomerization and tumorigenic mutations induce misfolding and loss of function. J. Mol. Biol. 2010, 395:705-716.
102. Lukman S., Lane D.P., Verma C.S. Mapping the structural and dynamical features of multiple p53 DNA binding domains: insights into loop 1 intrinsic dynamics. PLoS One 2013, 8:e80221.
103. Luo J., Li M., Tang Y., Laszkowska M., Roeder R.G., Gu W. Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:2259-2264.
104. Ma B., Levine A.J. Probing potential binding modes of the p53 tetramer to DNA based on the symmetries encoded in p53 response elements. Nucleic Acids Res. 2007, 35:7733-7747.
105. Madhumalar A., Jun L.H., Lane D.P., Verma C.S. Dimerization of the core domain of the p53 family: a computational study. Cell. Cycle 2009, 8:137-148.
106. Madhumalar A., Smith D.J., Verma C. Stability of the core domain of p53: insights from computer simulations. BMC Bioinform. 2008, 9(Suppl. 1):S17.
107. Mateu M.G., Fersht A.R. Nine hydrophobic side chains are key determinants of the thermodynamic stability and oligomerization status of tumour suppressor p53 tetramerization domain. EMBO J. 1998, 17:2748-2758.
108. Matsumoto M., Furihata M., Ohtsuki Y. Posttranslational phosphorylation of mutant p53 protein in tumor development. Med. Mol. Morphol. 2006, 39:79-87.
109. Mavinahalli J.N., Madhumalar A., Beuerman R.W., Lane D.P., Verma C. Differences in the transactivation domains of p53 family members: a computational study. BMC Genomics 2010, 11(Suppl. 1):S5.
110. McCoy M., Stavridi E.S., Waterman J.L., Wieczorek A.M., Opella S.J., Halazonetis T.D. Hydrophobic side-chain size is a determinant of the three-dimensional structure of the p53 oligomerization domain. EMBO J. 1997, 16:6230-6236.
111. McGrath J.A., Duijf P.H., Doetsch V., Irvine A.D., de Waal R., Vanmolkot K.R., Wessagowit V., Kelly A., Atherton D.J., Griffiths W.A., Orlow S.J., van Haeringen A., Ausems M.G., Yang A., McKeon F., Bamshad M.A., Brunner H.G., Hamel B.C., van Bokhoven H. Hay-Wells syndrome is caused by heterozygous missense mutations in the SAM domain of p63. Hum. Mol. Genet. 2001, 10:221-229.
112. McLure K.G., Lee P.W. How p53 binds DNA as a tetramer. EMBO J. 1998, 17:3342-3350.
113. Merabet A., Houlleberghs H., Maclagan K., Akanho E., Bui T.T., Pagano B., Drake A.F., Fraternali F., Nikolova P.V. Mutants of the tumour suppressor p53 L1 loop as second-site suppressors for restoring DNA binding to oncogenic p53 mutations: structural and biochemical insights. Biochem. J. 2010, 427:225-236.
114. Moll U.M., Petrenko O. The MDM2-p53 interaction. Mol. Cancer Res. 2003, 1:1001-1008.
115. Muller P.A., Caswell P.T., Doyle B., Iwanicki M.P., Tan E.H., Karim S., Lukashchuk N., Gillespie D.A., Ludwig R.L., Gosselin P., Cromer A., Brugge J.S., Sansom O.J., Norman J.C., Vousden K.H. Mutant p53 drives invasion by promoting integrin recycling. Cell 2009, 139:1327-1341.
116. Muller P.A., Vousden K.H. p53 mutations in cancer. Nat. Cell. Biol. 2013, 15:2-8.
117. Nagaich A.K., Zhurkin V.B., Durell S.R., Jernigan R.L., Appella E., Harrington R.E. p53-induced DNA bending and twisting: p53 tetramer binds on the outer side of a DNA loop and increases DNA twisting. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:1875-1880.
118. Narayanan A., Jacobson M.P. Computational studies of protein regulation by post-translational phosphorylation. Curr. Opin. Struct. Biol. 2009, 19:156-163.
119. Nikolova P.V., Henckel J., Lane D.P., Fersht A.R. Semirational design of active tumor suppressor p53 DNA binding domain with enhanced stability. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:14675-14680.
120. Noll J.E., Jeffery J., Al-Ejeh F., Kumar R., Khanna K.K., Callen D.F., Neilsen P.M. Mutant p53 drives multinucleation and invasion through a process that is suppressed by ANKRD11. Oncogene 2012, 31:2836-2848.
121. O'Farrell T.J., Ghosh P., Dobashi N., Sasaki C.Y., Longo D.L. Comparison of the effect of mutant and wild-type p53 on global gene expression. Cancer Res. 2004, 64:8199-8207.
122. Oda K., Arakawa H., Tanaka T., Matsuda K., Tanikawa C., Mori T., Nishimori H., Tamai K., Tokino T., Nakamura Y., Taya Y. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 2000, 102:849-862.
123. Olivier M., Eeles R., Hollstein M., Khan M.A., Harris C.C., Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum. Mutat. 2002, 19:607-614.
124. Olivier M., Goldgar D.E., Sodha N., Ohgaki H., Kleihues P., Hainaut P., Eeles R.A. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res. 2003, 63:6643-6650.
125. Olivier M., Hollstein M., Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb. Perspect. Biol. 2010, 2:a001008.
126. Pagel K., Natan E., Hall Z., Fersht A.R., Robinson C.V. Intrinsically disordered p53 and its complexes populate compact conformations in the gas phase. Angew. Chem. Int. Ed. Engl. 2013, 52:361-365.
127. Pan Y., Nussinov R. Structural basis for p53 binding-induced DNA bending. J. Biol. Chem. 2007, 282:691-699.
128. Pan Y., Nussinov R. Cooperativity dominates the genomic organization of p53-response elements: a mechanistic view. PLoS Comput. Biol. 2009, 5:e1000448.
129. Pan Y., Nussinov R. Lysine120 interactions with p53 response elements can allosterically direct p53 organization. PLoS Comput. Biol. 2010, 6.
130. Pan Y., Nussinov R. Preferred drifting along the DNA major groove and cooperative anchoring of the p53 core domain: mechanisms and scenarios. J. Mol. Recognit. 2010, 23:232-240.
131. Petitjean A., Mathe E., Kato S., Ishioka C., Tavtigian S.V., Hainaut P., Olivier M. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum. Mutat. 2007, 28:622-629.
132. Pintus S.S., Fomin E.S., Oshurkov I.S., Ivanisenko V.A. Phylogenetic analysis of the p53 and p63/p73 gene families. In Silico Biol. 2007, 7:319-332.
133. Popowicz G.M., Czarna A., Wolf S., Wang K., Wang W., Dömling A., Holak T.A. Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery. Cell. Cycle 2010, 9:1104-1111.
134. Qu L., Huang S., Baltzis D., Rivas-Estilla A.M., Pluquet O., Hatzoglou M., Koumenis C., Taya Y., Yoshimura A., Koromilas A.E. Endoplasmic reticulum stress induces p53 cytoplasmic localization and prevents p53-dependent apoptosis by a pathway involving glycogen synthase kinase-3beta. Genes. Dev. 2004, 18:261-277.
135. Rauf S.M., Ismael M., Sahu K.K., Suzuki A., Koyama M., Tsuboi H., Hatakeyama N., Endou A., Takaba H., Del Carpio C.A., Kubo M., Miyamoto A. The effect of R249S carcinogenic and H168R-R249S suppressor mutations on p53-DNA interaction, a multi scale computational study. Comput. Biol. Med. 2010, 40:498-508.
136. Rieber M., Strasberg-Rieber M. Hypoxia, Mn-SOD and H(2)O(2) regulate p53 reactivation and PRIMA-1 toxicity irrespective of p53 status in human breast cancer cells. Biochem. Pharmacol. 2012, 84:1563-1570.
137. Rodin S.N., Holmquist G.P., Rodin A.S. CpG transition strand asymmetry and hitch-hiking mutations as measures of tumorigenic selection in shaping the p53 mutation spectrum. Int. J. Mol. Med. 1998, 1:191-199.
138. Rodriguez M.S., Desterro J.M., Lain S., Midgley C.A., Lane D.P., Hay R.T. SUMO-1 modification activates the transcriptional response of p53. EMBO J. 1999, 18:6455-6461.
139. Rotter V. p53, a transformation-related cellular-encoded protein, can be used as a biochemical marker for the detection of primary mouse tumor cells. Proc. Natl. Acad. Sci. U. S. A. 1983, 80:2613-2617.
140. Sakaguchi K., Sakamoto H., Lewis M.S., Anderson C.W., Erickson J.W., Appella E., Xie D. Phosphorylation of serine 392 stabilizes the tetramer formation of tumor suppressor protein p53. Biochemistry 1997, 36:10117-10124.
141. Schon O., Friedler A., Bycroft M., Freund S.M., Fersht A.R. Molecular mechanism of the interaction between MDM2 and p53. J. Mol. Biol. 2002, 323:491-501.
142. Secchiero P., Bosco R., Celeghini C., Zauli G. Recent advances in the therapeutic perspectives of Nutlin-3. Curr. Pharm. Des. 2011, 17:569-577.
143. Shangary S., Wang S. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu. Rev. Pharmacol. Toxicol. 2009, 49:223-241.
144. Shieh S.Y., Ikeda M., Taya Y., Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 1997, 91:325-334.
145. Stad R., Little N.A., Xirodimas D.P., Frenk R., van der Eb A.J., Lane D.P., Saville M.K., Jochemsen A.G. Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms. EMBO Rep. 2001, 2:1029-1034.
146. Sykes S.M., Stanek T.J., Frank A., Murphy M.E., McMahon S.B. Acetylation of the DNA binding domain regulates transcription-independent apoptosis by p53. J. Biol. Chem. 2009, 284:20197-20205.
147. Tibbetts R.S., Brumbaugh K.M., Williams J.M., Sarkaria J.N., Cliby W.A., Shieh S.Y., Taya Y., Prives C., Abraham R.T. A role for ATR in the DNA damage-induced phosphorylation of p53. Genes. Dev. 1999, 13:152-157.
148. Unger T., Juven-Gershon T., Moallem E., Berger M., Vogt Sionov R., Lozano G., Oren M., Haupt Y. Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. EMBO J. 1999, 18:1805-1814.
149. Vassilev L.T. MDM2 inhibitors for cancer therapy. Trends Mol. Med. 2007, 13:23-31.
150. Vaughan C.A., Frum R., Pearsall I., Singh S., Windle B., Yeudall A., Deb S.P., Deb S. Allele specific gain-of-function activity of p53 mutants in lung cancer cells. Biochem. Biophys. Res. Commun. 2012, 428:6-10.
151. Vaziri H., Dessain S.K., Ng Eaton E., Imai S.I., Frye R.A., Pandita T.K., Guarente L., Weinberg R.A. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001, 107:149-159.
152. Verdine G.L., Walensky L.D. The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members. Clin. Cancer Res. 2007, 13:7264-7270.
153. Walensky L.D., Kung A.L., Escher I., Malia T.J., Barbuto S., Wright R.D., Wagner G., Verdine G.L., Korsmeyer S.J. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 2004, 305:1466-1470.
154. Walerych D., Napoli M., Collavin L., Del Sal G. The rebel angel: mutant p53 as the driving oncogene in breast cancer. Carcinogenesis 2012, 33:2007-2017.
155. Walker D.R., Bond J.P., Tarone R.E., Harris C.C., Makalowski W., Boguski M.S., Greenblatt M.S. Evolutionary conservation and somatic mutation hotspot maps of p53: correlation with p53 protein structural and functional features. Oncogene 1999, 18:211-218.
156. 2+ in the p53 DNA-binding domain: insights from computational studies. Phys. Chem. Chem. Phys. 2011, 13:1140-1151.
157. Wang Y., Rosengarth A., Luecke H. Structure of the human p53 core domain in the absence of DNA. Acta Crystallogr. D - Biol. Crystallogr. 2007, 63:276-281.
158. Wassman C.D., Baronio R., Demir Ö., Wallentine B.D., Chen C.K., Hall L.V., Salehi F., Lin D.W., Chung B.P., Hatfield G.W., Richard Chamberlin A., Luecke H., Lathrop R.H., Kaiser P., Amaro R.E. Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53. Nat. Commun. 2013, 4:1407.
159. Waterman M.J., Stavridi E.S., Waterman J.L., Halazonetis T.D. ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins. Nat. Genet. 1998, 19:175-178.
160. Wei S.J., Joseph T., Sim A.Y., Yurlova L., Zolghadr K., Lane D., Verma C., Ghadessy F. In vitro selection of mutant HDM2 resistant to Nutlin inhibition. PLoS One 2013, 8:e62564.
161. Weinberg R.L., Veprintsev D.B., Fersht A.R. Cooperative binding of tetrameric p53 to DNA. J. Mol. Biol. 2004, 341:1145-1159.
162. Wells M., Tidow H., Rutherford T.J., Markwick P., Jensen M.R., Mylonas E., Svergun D.I., Blackledge M., Fersht A.R. Structure of tumor suppressor p53 and its intrinsically disordered N-terminal transactivation domain. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:5762-5767.
163. Wright J.D., Noskov S.Y., Lim C. Factors governing loss and rescue of DNA binding upon single and double mutations in the p53 core domain. Nucleic Acids Res. 2002, 30:1563-1574.
164. Xu J., Reumers J., Couceiro J.R., De Smet F., Gallardo R., Rudyak S., Cornelis A., Rozenski J., Zwolinska A., Marine J.C., Lambrechts D., Suh Y.A., Rousseau F., Schymkowitz J. Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. Nat. Chem. Biol. 2011, 7:285-295.
165. Xu Y. Regulation of p53 responses by post-translational modifications. Cell. Death Differ. 2003, 10:400-403.
166. Yamaguchi H., Woods N.T., Piluso L.G., Lee H.H., Chen J., Bhalla K.N., Monteiro A., Liu X., Hung M.C., Wang H.G. p53 acetylation is crucial for its transcription-independent proapoptotic functions. J. Biol. Chem. 2009, 284:11171-11183.
167. Yang A., Kaghad M., Wang Y., Gillett E., Fleming M.D., Dötsch V., Andrews N.C., Caput D., McKeon F. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol. Cell. 1998, 2:305-316.
168. Yang A., Schweitzer R., Sun D., Kaghad M., Walker N., Bronson R.T., Tabin C., Sharpe A., Caput D., Crum C., McKeon F. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999, 398:714-718.
169. Yang A., Walker N., Bronson R., Kaghad M., Oosterwegel M., Bonnin J., Vagner C., Bonnet H., Dikkes P., Sharpe A., McKeon F., Caput D. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 2000, 404:99-103.
170. Yi L., Lu C., Hu W., Sun Y., Levine A.J. Multiple roles of p53-related pathways in somatic cell reprogramming and stem cell differentiation. Cancer Res. 2012, 72:5635-5645.
171. Yu X., Vazquez A., Levine A.J., Carpizo D.R. Allele-specific p53 mutant reactivation. Cancer Cell. 2012, 21:614-625.
172. Zache N., Lambert J.M., Rökaeus N., Shen J., Hainaut P., Bergman J., Wiman K.G., Bykov V.J. Mutant p53 targeting by the low molecular weight compound STIMA-1. Mol. Oncol. 2008, 2:70-80.
173. Zache N., Lambert J.M., Wiman K.G., Bykov V.J. PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53. Cell. Oncol. 2008, 30:411-418.
174. Zhang Y., Yan W., Chen X. Mutant p53 disrupts MCF-10A cell polarity in three-dimensional culture via epithelial-to-mesenchymal transitions. J. Biol. Chem. 2011, 286:16218-16228.